Clinical Trial Update: 4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated three oral doses of BI 10773 over four weeks in adults with type 2 diabetes; the study has completed and results were posted in Aug…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BI 10773

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED | Results posted: 2014-08-07